EGFR and glioma: In an immunocompetent host, the combination of OV-IL15C and EGFR-CAR NK significantly enhanced endogenous NK and CD8+ T-cell infiltration, improved the persistence of EGFR-CAR NK-cells within the tumor site, and prolonged the survival of glioma-bearing mice.